Fetoscopic endoluminal tracheal occlusion with Smart-TO balloon: Study protocol to evaluate effectiveness and safety of non-invasive removal.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 15 08 2022
accepted: 24 01 2023
entrez: 13 3 2023
pubmed: 14 3 2023
medline: 16 3 2023
Statut: epublish

Résumé

One of the drawbacks of fetoscopic endoluminal tracheal occlusion (FETO) for congenital diaphragmatic hernia is the need for a second invasive intervention to reestablish airway patency. The "Smart-TO" (Strasbourg University-BSMTI, France) is a new balloon for FETO, which spontaneously deflates when positioned near a strong magnetic field, e.g., generated by a magnetic resonance image (MRI) scanner. Translational experiments have demonstrated its efficacy and safety. We will now use the Smart-TO balloon for the first time in humans. Our main objective is to evaluate the effectiveness of prenatal deflation of the balloon by the magnetic field generated by an MRI scanner. These studies were first in human (patients) trials conducted in the fetal medicine units of Antoine-Béclère Hospital, France, and UZ Leuven, Belgium. Conceived in parallel, protocols were amended by the local Ethics Committees, resulting in some minor differences. These trials were single-arm interventional feasibility studies. Twenty (France) and 25 (Belgium) participants will have FETO with the Smart-TO balloon. Balloon deflation will be scheduled at 34 weeks or earlier if clinically required. The primary endpoint is the successful deflation of the Smart-TO balloon after exposure to the magnetic field of an MRI. The secondary objective is to report on the safety of the balloon. The percentage of fetuses in whom the balloon is deflated after exposure will be calculated with its 95% confidence interval. Safety will be evaluated by reporting the nature, number, and percentage of serious unexpected or adverse reactions. These first in human (patients) trials may provide the first evidence of the potential to reverse the occlusion by Smart-TO and free the airways non-invasively, as well a safety data.

Identifiants

pubmed: 36913364
doi: 10.1371/journal.pone.0273878
pii: PONE-D-22-21857
pmc: PMC10010565
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0273878

Informations de copyright

Copyright: © 2023 Sananès et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

’Nicolas Sananès is the primary co-inventor of the Smart-TO balloon. None of the authors has any financial interest in BS‐Medical Tech Industry, manufacturing the balloon. There are no other conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Stat Med. 1993 May 15;12(9):809-24
pubmed: 8327801
Prenat Diagn. 2019 Apr;39(5):403-408
pubmed: 30861154
N Engl J Med. 2021 Jul 8;385(2):119-129
pubmed: 34106555
J Pediatr Surg. 2011 Jan;46(1):22-32
pubmed: 21238635
Ultrasound Obstet Gynecol. 2020 Oct;56(4):522-531
pubmed: 32602968
Am J Obstet Gynecol. 2022 Apr;226(4):560.e1-560.e24
pubmed: 34808130
N Engl J Med. 2021 Jul 8;385(2):107-118
pubmed: 34106556
Ultrasound Obstet Gynecol. 2013 Jul;42(1):77-83
pubmed: 23444265
Semin Pediatr Surg. 2017 Jun;26(3):123-128
pubmed: 28641748
Gynecol Surg. 2018;15(1):9
pubmed: 29770109
Am J Obstet Gynecol. 2017 Jul;217(1):78.e1-78.e11
pubmed: 28267443
Ultrasound Obstet Gynecol. 2021 Jan;57(1):105-112
pubmed: 33012007
Eur J Pediatr Surg. 2017 Aug;27(4):297-305
pubmed: 27522127
Ultrasound Obstet Gynecol. 2021 Mar;57(3):378-385
pubmed: 32924187

Auteurs

Nicolas Sananès (N)

Department of Maternal Fetal Medicine, Strasbourg University Hospital, Strasbourg, France.
INSERM 1121 'Biomaterials and Bioengineering', Strasbourg University, Strasbourg, France.

David Basurto (D)

MyFetUZ Fetal Research Center, Department of Development and Regeneration, Cluster Woman and Child, Biomedical Sciences, KU Leuven, Leuven, Belgium.

Anne-Gaël Cordier (AG)

Department of Maternal fetal Medicine, Antoine-Béclère Hospital - Paris-Saclay University, Clamart, France.

Caroline Elie (C)

Clinical Research Unit/Clinical Investigation Center, Necker-Enfants Malades Hospital, Paris, France.

Francesca Maria Russo (FM)

MyFetUZ Fetal Research Center, Department of Development and Regeneration, Cluster Woman and Child, Biomedical Sciences, KU Leuven, Leuven, Belgium.
Clinical Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.

Alexandra Benachi (A)

Department of Maternal fetal Medicine, Antoine-Béclère Hospital - Paris-Saclay University, Clamart, France.

Jan Deprest (J)

MyFetUZ Fetal Research Center, Department of Development and Regeneration, Cluster Woman and Child, Biomedical Sciences, KU Leuven, Leuven, Belgium.
Clinical Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.
Institute for Women's Health, University College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH